Research & development
The ability of our Research & Development teams to create innovative, meaningful products and solutions for customers is a
critical driver of Philips’ competitiveness in its markets. Through substantial R&D investments, Philips has created a vast
knowledge and intellectual property base. Early involvement of customers in new technologies, as well as in product and business
concepts, ensures deep insight into their needs – the foundation for our innovations. Starting in 2009, in an effort to generate
more profitable growth and new product and market development from our R&D investments, Philips will redirect EUR 250 million
of innovation spending from mature to emerging market areas. The redirection of innovation is guided by the newly-formed Philips
Innovation board, chaired by Philips’ CEO, and the Company’s chief officers of Technology, Strategy, Marketing and Design.
In 2008, Philips’ investment in R&D activities amounted to EUR 1,622 million (6.1% of sales), compared with EUR 1,629 million
(6.1% of sales) in 2007. Higher expenditures at Healthcare and Lighting were fully offset by lower expenditures at Consumer
Lifestyle. Also, investments in innovative technologies increased in areas such as energy-efficient and solid-state lighting
solutions as well as in the areas of health and wellness. These increases were offset by lower expenditures in more mature
technologies, such as lamps and television.
|
Research and development expenditures per sector
1,2)
in millions of euros
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Healthcare R&D expenditures increased in 2008, mainly due to the acquisition of Respironics. Lighting’s expenditures were
also above 2007 as a result of the acquisition of Genlyte and higher investments in energy-efficient and solid-state lighting
solutions. The lower R&D expenditures within Consumer Lifestyle were mainly due to lower expenditures in maturing product
categories, such as Television. Furthermore, R&D investments at Innovation & Emerging Businesses were on par with 2007, as
higher investments in the Incubator activities were offset by lower external contract research.
Philips' strong innovation pipeline contributed positively to the Company's sales in 2008, as 58% of Group sales came from
newly introduced products – products introduced within the last year (for B2C products) or three years (for B2B products).
Compared to last year, a 2% improvement was seen thanks to above-average contributions from Healthcare and Consumer Lifestyle.
Philips aims to maintain its new-product-to-sales ratio above 50%, while at the same time focusing on the profitability of
new products and reallocating innovation spend more towards new business creation.
|